In the past year, IV’s latest passive vaccine storage device, or Arktek™, as it’s now known, has emerged on the scene in the ongoing effort to eradicate some of the world’s deadliest diseases that are still prominent in parts of the developing world.

IV’s Passive Vaccine Storage Device, PBS Feature
All Stories

IV’s Passive Vaccine Storage Device, PBS Feature

In the past year, IV’s latest passive vaccine storage device, or Arktek™, as it’s now known, has emerged on the scene in the ongoing effort to eradicate some of the world’s deadliest diseases that are still prominent in parts of the developing world. The World Health Organization (WHO) and the Centers for Disease Control (CDC) tagged Arktek to help make Ebola vaccine trials in Sierra Leone and Guinea possible.

In the PBS NewsHour segment, “Why testing an Ebola vaccine isn’t so easy,” science correspondent Miles O'Brian reports on the challenges of conducting experimental drug trials in Sierra Leone and Liberia. In the following segment – starting at the 1:30 mark – see how The Deep Freeze Arktek comes into play at times when severe temperatures and unreliable power would otherwise threaten to spoil the life-saving vaccines that many are counting on.

 

 

Arktek allows researchers on the ground in Africa to determine the efficacy of Ebola vaccine candidates. An important requirement in keeping the Ebola vaccine effective throughout the trials is to keep the vaccines at appropriate temperatures until being thawed for injection. And these vaccines require unusually low temperatures during storage, transportation, and distribution.

Prior to its use in vaccine trials, the WHO awarded Arktek prequalified status, an important prerequisite to introducing the device to most countries in the developing world. The status is effectively a stamp of approval for real-world use, and it’s enabling Arktek, as well as modified versions, to be used on the ground in the fight against other vaccine-preventable diseases.

Without the unique cold chain properties of Arktek, it would not be possible to maintain the necessary temperatures to transport and distribute the Ebola vaccine candidates in remote areas without reliable electricity, where they require storage at temperatures below -60°C (-76°F) for a number of days before use. We’re grateful to the scientists and engineers who’ve worked diligently to address the challenging problems that come with the territory when keeping something so cold for so long without power.


Breakthroughs like these power our belief that invention is the driver of all progress. Learn more about Arktek here. Intellectual Ventures. A global inventions company.

The End